Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Brazil Health Ministry expects at least 150 mln vaccine doses by June

Tue, 22nd Dec 2020 22:03

(Adds details of vaccine delivery, pending deals)

By Lisandra Paraguassu

BRASILIA, Dec 22 (Reuters) - Brazil's Health Ministry
expects to have at least 150 million doses of vaccines against
COVID-19 available in the first half of 2021, with a third or
more coming from a Chinese company despite the president's early
skepticism.

Arnaldo Medeiros, a health ministry official, also told a
congressional hearing on Tuesday that an initial deal to acquire
46 million doses of vaccine developed by China's Sinovac Biotech
could soon be expanded to 100 million doses.

The Sao Paulo state government's Butantan Institute is
expected on Wednesday to present data from its late-stage trial
of the Sinovac vaccine, called CoronaVac, which has already
begun rolling off its fill-and-finish production line.

President Jair Bolsonaro had snubbed that vaccine, citing
doubts about its "origin" and trading barbs with Sao Paulo
Governor Joao Doria, a political rival. But the Health Ministry
has been eager to secure supplies of it as the global rush for
vaccines heats up.

The federal government's Fiocruz biomedical center is also
expected to begin fill-and-finish of the AstraZeneca
vaccine in coming months, delivering the first shots on Feb. 8.
The ministry expects 104 million doses by June, officials said.

Separately, the ministry is in talks with Pfizer Inc
to receive 8 million doses of the vaccine it developed with
Germany's BioNTech SE in the first half of 2021.

No COVID-19 vaccine has been approved yet for use in Brazil.
The Pfizer/BioNTech shot has been authorized in several
countries, including the United States, the UK and Canada.

Bolsonaro, who has repeatedly played down the severity of
the pandemic, has said he will not take any vaccine, stoking
broader skepticism toward the shots among Brazilians. Brazil's
public health authorities, however, have said they will use any
vaccine approved by regulators.
(Reporting by Lisandra Paraguassu
Writing by Sabrina Valle and Marcelo Rochabrun; Editing by Brad
Haynes and Bill Berkrot)

More News
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more
6 Sep 2023 07:45

AstraZeneca working with FDA on finer details of Ultomiris treatment

(Sharecast News) - Pharma giant AstraZeneca said it is "working closely" with US regulators to clarify some details of its Ultomiris drug as it hopes to bring the treatment to market as quickly as possible for people suffering from the rare disease, neuromyelitis optica spectrum disorder (NMOSD).

Read more
4 Sep 2023 15:46

UK dividends calendar - next 7 days

Tuesday 5 September 
no events scheduled 
Wednesday 6 September 
no events scheduled 
Thursday 7 September 
Admiral Group PLCex-dividend payment date
Alpha Financial Markets Consulting PLCex-dividend payment date
Anglo-Eastern Plantations PLCex-dividend payment date
Assura PLCex-dividend payment date
Athelney Trust PLCex-dividend payment date
Baltic Classifieds Group PLCex-dividend payment date
Blackrock World Mining Trust PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
CT UK Capital & Income Investment Trust PLCex-dividend payment date
Derwent London PLCex-dividend payment date
Develop North PLCex-dividend payment date
DS Smith PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Greggs PLCex-dividend payment date
Harbour Energy PLCex-dividend payment date
Pollen Street PLCex-dividend payment date
Prudential PLCex-dividend payment date
Relx PLCdividend payment date
RM Infrastructure Income PLCex-dividend payment date
Serco Group PLCex-dividend payment date
Severfield PLCex-dividend payment date
VPC Specialty Lending Investments PLCex-dividend payment date
XP Power Ltdex-dividend payment date
Zotefoams PLCex-dividend payment date
Friday 8 September 
abrdn New Dawn Investment Trust PLCdividend payment date
Avon Protection PLCdividend payment date
Berkeley Group Holdings PLCdividend payment date
Chemring Group PLCdividend payment date
Ecofin US Renewables Infrastructure Trust PLCdividend payment date
iomart Group PLCdividend payment date
Keller Group PLCdividend payment date
Lookers PLCdividend payment date
Moneysupermarket.com Group PLCdividend payment date
Nichols PLCdividend payment date
Tritax EuroBox PLCdividend payment date
Tyman PLCdividend payment date
Monday 11 September 
AstraZeneca PLCdividend payment date
Games Workshop Group PLCdividend payment date
Rentokil Initial PLCdividend payment date
Residential Secure Income PLCdividend payment date
ThomasLloyd Energy Impact Trust PLCdividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
4 Sep 2023 12:13

LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks

(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic.

Read more
4 Sep 2023 08:25

IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

Read more
4 Sep 2023 07:36

LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed

(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment.

Read more
29 Aug 2023 20:24

Blood thinners, diabetes meds among first 10 drugs for US price negotiations

Aug 29(Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.